India's CDSCO has warned pharma firms against promoting prescription weight-loss drugs (GLP-1s) via surrogate or digital ads, ...

The Drugs Controller General of India (DCGI) has issued strict warning against any surrogate advertisements, including awareness campaigns, for presc ...

Researchers develop a modified high-resolution magnetic resonance imaging technique for determining the location of ...

NEW DELHI, March 12, 2026 — India’s top drug regulator has issued an advisory cautioning pharmaceutical firms against promoting prescription obesity drugs through indirect marketing practices such as ...

Today the Board of Directors appointed Ian Bickley as Chairman and Chief Executive Officer of Vera Bradley. For the past eight months, Mr. Bickley has served as Executive Chairman and has been deeply ...

As blockbuster weight-loss drugs surge in India, regulators warn that "awareness campaigns" may be blurring the line between public health messaging and pharmaceutical marketing.

The Central Drugs Standard Control Organization (CDSCO) has issued an advisory cautioning pharmaceutical companies against direct or indirect promotional activities related to ...

The CDSCO advisory bars direct and indirect promotion of GLP-1 weight-loss drugs, including influencer campaigns and awareness content that create brand recall among consumers ...

CDSCO issues advisory against promotional activities for anti-obesity, metabolic disorder drugs: Our Bureau, New Delhi Thursday, March 12, 2026, 12:45 Hrs [IST] The Central Drugs ...

This prohibition shall extend to any form of direct or indirect promotional activity in print, electronic, digital, social media, or any other public platform that is intended, directly or indirectly, ...

This report was published from a syndicated wire feed. Apart from the headline, the EdexLive Desk has not edited the copy.

GLP-1 receptor agonists have gained global attention for their weight-loss benefits. In India, the segment currently has two ...